AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said, “The news reinforces Tagrisso as the backbone ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

has recommended approval of Lazcluze in combination with Rybrevant for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). The CHMP ...

The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally ...

LUPKYNIS, the only FDA-approved CNI therapy for the treatment of adult patients with active LN in combination with other immunosuppressive therapies , has demonstrated broad clinical utility across ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside ...

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

IgA nephropathy trials of new and emerging therapies that target B cell activity, the complement system, or the endothelin ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...